Novel Buspirone-Like 5-HT 1A Receptor Ligands

• Autorzy: Krajewski K. , Leś A. , Cybulski J. , Chilmonczyk Z. , Bronowska A. , Szelejewska-Woźniakowska A.
• Języki publikacji: EN

Abstrakty

EN

Four novel buspirone-like compounds were synthesized and their affinity to the serotonin 5-HT1A receptor was determined. Two compounds bind to 5-HT1A receptor with a high affinity and two other compounds exhibit a low affinity to this receptor. A simple two-parameter polynomial correlation was suggested to express the structure-activity relationships.

Słowa kluczowe

EN

anxiolitics; pharmacophores; conformational analysis; structure-activity; relationships

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2001
• Tom: Vol. 75, nr 1
• Strony: 71--78
• Opis fizyczny: Bibliogr. 21 poz., rys.

Twórcy

autor

Krajewski K.

• Pharmaceutical Reaserch Institute, 8 Rydygiera Str., 01-793 Warszawa, Poland

autor

Leś A.

• Pharmaceutical Reaserch Institute, 8 Rydygiera Str., 01-793 Warszawa, Poland
• Departament of Chemistry, University of Warsaw, 1 Pasteura Str., 02-093 Warszawa, Poland

autor

Cybulski J.

• Pharmaceutical Reaserch Institute, 8 Rydygiera Str., 01-793 Warszawa, Poland

autor

Chilmonczyk Z.

• Drug Institute, 30/34 Chełmska Str., 00-725 Warszawa, Poland

autor

Bronowska A.

• Departament of Chemistry, University of Warsaw, 1 Pasteura Str., 02-093 Warszawa, Poland

autor

Szelejewska-Woźniakowska A.

• Pharmaceutical Reaserch Institute, 8 Rydygiera Str., 01-793 Warszawa, Poland

Bibliografia

• 1. Riblet L.A., Taylor D.P,, Eison M.S. and Stanton H.C., J. Clin. Psychiatry, 43, 11 (1982).
• 2. Goa K. and Ward A., Drugs, 32, 114 (1986).
• 3. Ishizumi K., Kojima A. and Antoku R, Chem. Pharm. Bull., 39, 2288 (1991).
• 4. Kuribara H., Jpn J. Pharmacol., 64, 273 (1994).
• 5. Costall B., Domeney A.M., Farre A.J., Kelly M.E. and Martinez L., J. Pharmacol. Exp. Ther., 262, 90 (1992).
• 6. Albitisson A,,Bjork A.,Svartengren J., KlintT. and Andersson G., Eur. J. Pharmacol., 261,285 (1994).
• 7. Laufumey L.S., Haj-Dahmane S. and Hamon M., Eur. J. Pharmacol., 249, 25 (1993).
• 8. Chilmonczyk Z., J. Pharm. Pharmacol., 47, 791 (1995).
• 9. Lloyd E. J. and Andrews P. R., J. Med. Chem., 29,453 (1986).
• 10. Hibert M.F.,GittosM.W., Middlemiss D.N., Mir A.K. and FozardJ.R., J. Med. Chem.,31,1087 (1988).
• 11. Hacksell U., Mellin C., IIillver S.-E., Bjórk L., Cornfield L.J., Nelson D.L. and Lewander T., Xith Int. Symp, on Med. Chem. Jerusalem, Israel, 2-7 Sept., In Trends in Medicinal Chemistry Proc., p. 13 (1990).
• 12. Mellin C., Vallgarda J., Nelson D.L., Bjork L., Yu H., Andén N.-E., Csóregh I., Arvidsson L. -E. and Hacksell U., J. Med. Chem., 34, 497 (1991),
• 13. Agarwal A. and Taylor E.W., J. Comp, Chem,, 14,237 (1991).
• 14. Mokrosz M.J., Duszyńska B., Bojarski A. and Mokrosz, J.L., Bioorg. Med. Chem., 3, 533 (1995).
• 15. Van Steen B.J., van Wijngaarden I., Tulp M.Th.M. and Soudijn W., J. Med. Chem., 37, 2761 (1994).
• 16. Chilmonczyk Z., Szelejewska-Woźniakowska A., Cybulski J., Cybulski M., Kozio! A.E. and Gdaniec M., Arch. Pharm., 330, 146 (1997).
• 17. Glennon A.R., Naiman A.N., Lyon R.A. and Titeler M., J. Med. Chem., 31, 1968 (1988).
• 18. Hoyer D. and Schoeffter P., J. Receptor Res., 11, 197 (1991).
• 19. Fourneau M.M.E. and Barrelet Ch. E., Bull. Soc. Chim. France, 45, 1172 (1929).
• 20. Alhaider Abdulqader A., J. Pharm. Sci., 81, 99 (1992).
• 21. Hall M.D., El Mestikawy S., Emerit M.B., Pichat L., Hamon M. and Gozlan H., J. Neurochem., 44,1685 (1985).